Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT05421416

Loratadine for the Prevention of G-CSF-related Bone Pain

Led by AHS Cancer Control Alberta · Updated on 2026-02-05

78

Participants Needed

1

Research Sites

104 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The research question for the current study is: Is loratadine more effective than placebo in preventing G-CSF-related bone pain during autologous hematopoetic stem cell transplant in patients with lymphoma or multiple myeloma? The hypothesis is that prophylaxis with loratadine will help prevent or reduce the severity of bone pain in this setting.

CONDITIONS

Official Title

Loratadine for the Prevention of G-CSF-related Bone Pain

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically or cytologically confirmed lymphoma or multiple myeloma
  • Planned autologous stem cell transplant as next line of therapy
  • Adults aged 18 years or older
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
  • Life expectancy of at least 12 weeks
  • No additional poorly controlled systemic diseases that contraindicate participation or pose significant risk, including congestive heart failure, diabetes mellitus, cirrhosis or liver failure, renal failure
  • Ability to follow study protocols and attend scheduled visits
Not Eligible

You will not qualify if you...

  • Known hypersensitivity or intolerance to antihistamines
  • Use of antihistamines within two days prior to the study period, except single doses during chemotherapy or blood transfusion protocols
  • Use of granulocyte colony stimulating factor (G-CSF) or pegfilgrastim within 12 weeks before study enrollment
  • New and regular use of pain medications within four days before the first dose of G-CSF

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Cross Cancer Institute

Edmonton, Alberta, Canada, T6G 1Z2

Actively Recruiting

Loading map...

Research Team

M

Michael Chu, MD

CONTACT

R

Rammy Khadour

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here